Art. 251 Comprehensive and enhanced Partnership Agreement between the European Union and the Euro…

Protection of data submitted to obtain an authorisation to put a medicinal product on the market

In forcesince 24 Nov 2017
1.

Each Party shall protect commercially confidential information submitted to obtain an authorisation to put a medicinal product on the market (‘marketing authorisation’) against disclosure to third parties, unless overriding health interests provide otherwise. Any confidential business information shall also benefit from protection against unfair commercial practices.

2.

Each Party shall ensure that, for a period of eight years from the first marketing authorisation in the Party concerned, the public body responsible for the granting of a marketing authorisation shall not take into account confidential business information or the results of pre-clinical tests or clinical trials provided in the first marketing authorisation application and subsequently submitted by a person or entity, whether public or private, in support of another application for authorisation to place a medicinal product on the market without the explicit consent of the person or entity who submitted such data, unless international agreements recognised by both Parties provide otherwise.

3.

During a ten-year period, starting from the date of granting of the first marketing authorisation in the Party concerned, a marketing authorisation granted for any subsequent application based on the results of pre-clinical tests or of clinical trials provided in the first marketing authorisation shall not permit placing a medicinal product on the market, unless the subsequent applicant submits his own results of pre-clinical tests or of clinical trials (or results of pre-clinical tests or of clinical trials used with the consent of the party which had provided that information) fulfilling the same requirements as the first applicant.

Products not complying with the requirements set out in this paragraph shall not be allowed on the market.

4.

In addition, the ten-year period referred to in paragraph 3 shall be extended to a maximum of 11 years if, during the first eight years after obtaining the authorisation, the authorisation holder obtains authorisation for one or more new therapeutic indications which are considered to bring a significant clinical benefit in comparison with existing therapies.